Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 75
- Registration Number
- NCT05272826
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
- Conditions
- Multiple Myeloma
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 72
- Registration Number
- NCT04786028
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Nova Scotia Health - QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Hamilton Health Sciences Centre, Hamilton, Ontario, Canada
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Canadian Myeloma Research Group
- Registration Number
- NCT04258683
- Locations
- 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦The Moncton Hospital, Moncton, New Brunswick, Canada
🇨🇦CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 120
- Registration Number
- NCT03715478
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT03697629
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada
- Prev
- 1
- 2
- Next